Summary & Overview

CPT 0029U: Focused Pharmacogenomics Panel, Mayo Clinic

CPT code 0029U designates a Proprietary Laboratory Analyses (PLA) test: the Focused Pharmacogenomics Panel developed and offered by the Mayo Clinic. As a PLA CPT code, 0029U corresponds to one unique, brand- or lab-specific assay that provides pharmacogenomic information to guide medication selection and dosing. This type of testing is increasingly relevant nationally as precision medicine grows and clinicians seek genetic insights to reduce adverse drug events and optimize therapy.

Key payers included in national coverage discussions are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise outline of the clinical purpose of the test, typical sites where the service is delivered, and the role such PLA codes play in coding and billing workflows. The publication reviews payer coverage themes and benchmarking considerations for PLA pharmacogenomic assays, summarizes common modifier usage patterns, and situates 0029U within the broader trend of proprietary molecular diagnostics entering standard clinical practice.

This summary provides policy and billing stakeholders with the essential context needed to understand what 0029U represents, which payers are commonly addressed in coverage discussions, and what topics—coverage benchmarks, coding implications, and clinical utility—are covered in the full analysis. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0029UCPTProprietary Laboratory AnalysesPharmacogenomicsMolecular DiagnosticsLaboratory TestingPrecision Medicine

Billing Code Overview

CPT code 0029U is a Proprietary Laboratory Analyses (PLA) code that describes a single, manufacturer- or lab-specific test: the Focused Pharmacogenomics Panel from the Mayo Clinic. This panel analyzes a targeted set of genes to inform medication selection and dosing based on a patient’s genetic profile.

Service type: Laboratory genetic testing (proprietary pharmacogenomics panel)
Typical site of service: Clinical laboratory or specialized molecular diagnostics facility associated with the Mayo Clinic

Clinical & Coding Specifications

Clinical Context

A 58-year-old patient with a history of multiple chronic conditions, including major depressive disorder and atrial fibrillation, is evaluated by a primary care physician and a clinical pharmacist for medication optimization after a recent adverse drug reaction. The clinician orders the Mayo Clinic Focused Pharmacogenomics Panel (0029U) to identify clinically relevant germline variants in pharmacokinetic and pharmacodynamic genes that influence response to commonly prescribed psychiatric and cardiovascular medications. Blood is drawn in an outpatient clinic or at a hospital ambulatory lab; the specimen is sent to the Mayo Clinic laboratory for analysis. Results are returned as a targeted report indicating variant alleles and recommended medication gene interactions to inform prescribing decisions. The typical workflow includes pre-test counseling, specimen collection (venipuncture), laboratory processing and bioinformatic analysis, result reporting to the ordering provider, and a follow-up visit or medication adjustment by the prescriber or clinical pharmacist.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier; default billing indicator	Use when no special circumstances apply to the service.
`26`

Taxonomy Code	Specialty	Notes
208000000X	Medical Genetics	Clinical geneticists or molecular pathologists who interpret pharmacogenomic results.
207Q00000X	Clinical Pathology	Pathologists and laboratory directors overseeing test validation and reporting.
2084P0800X	Clinical Pharmacology	Clinical pharmacologists or pharmacogenomics specialists advising on medication adjustments.
363LP0800X	Clinical Laboratory	Laboratory professionals managing specimen processing and sequencing workflows.
208000000X	Internal Medicine — Subspecialty overlap	Primary care or specialty physicians who order and act on results.

ICD-10 Code	Description	Clinical Relevance
`Z13.79`	Encounter for screening for other metabolic disorders	Used when screening for pharmacogenomic risk factors prior to medication changes.
`F32.9`	Major depressive disorder, single episode, unspecified	Common indication for medications affected by pharmacogenomic variants included on the panel.
`I48.91`	Unspecified atrial fibrillation	Anticoagulant choice and dosing may be influenced by pharmacogenomic testing.
`G43.909`	Migraine, unspecified, not intractable, without status migrainosus	Some migraine therapies are affected by enzyme variants assessed in the panel.
`R53.83`	Other fatigue	Symptom prompting medication review where pharmacogenomic results may guide therapy.

CPT Code	Description	Relationship to This Procedure
`81002`	Urinalysis, by dip stick or tablet reagent; non-automated, without microscopy	Data not available in the input.
`36415`	Collection of venous blood by venipuncture	Commonly performed immediately before `0029U` to obtain the specimen for pharmacogenomic testing.
`88360`	Immunohistochemistry, per single antigen; initial antibody stain	Data not available in the input.
`80400`	Drug assay, qualitative; multiple drug classes	Data not available in the input.
`0000U`	Proprietary Laboratory Analyses (example PLA)	Data not available in the input.

OpenPayer